BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1553 related articles for article (PubMed ID: 31466926)

  • 1. Blocking CD38-driven fratricide among T cells enables effective antitumor activity by CD38-specific chimeric antigen receptor T cells.
    Gao Z; Tong C; Wang Y; Chen D; Wu Z; Han W
    J Genet Genomics; 2019 Aug; 46(8):367-377. PubMed ID: 31466926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reversible Transgene Expression Reduces Fratricide and Permits 4-1BB Costimulation of CAR T Cells Directed to T-cell Malignancies.
    Mamonkin M; Mukherjee M; Srinivasan M; Sharma S; Gomes-Silva D; Mo F; Krenciute G; Orange JS; Brenner MK
    Cancer Immunol Res; 2018 Jan; 6(1):47-58. PubMed ID: 29079655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An "off-the-shelf" fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies.
    Cooper ML; Choi J; Staser K; Ritchey JK; Devenport JM; Eckardt K; Rettig MP; Wang B; Eissenberg LG; Ghobadi A; Gehrs LN; Prior JL; Achilefu S; Miller CA; Fronick CC; O'Neal J; Gao F; Weinstock DM; Gutierrez A; Fulton RS; DiPersio JF
    Leukemia; 2018 Sep; 32(9):1970-1983. PubMed ID: 29483708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase.
    Walker AJ; Majzner RG; Zhang L; Wanhainen K; Long AH; Nguyen SM; Lopomo P; Vigny M; Fry TJ; Orentas RJ; Mackall CL
    Mol Ther; 2017 Sep; 25(9):2189-2201. PubMed ID: 28676342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Rational Strategy for Reducing On-Target Off-Tumor Effects of CD38-Chimeric Antigen Receptors by Affinity Optimization.
    Drent E; Themeli M; Poels R; de Jong-Korlaar R; Yuan H; de Bruijn J; Martens ACM; Zweegman S; van de Donk NWCJ; Groen RWJ; Lokhorst HM; Mutis T
    Mol Ther; 2017 Aug; 25(8):1946-1958. PubMed ID: 28506593
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 8. A novel chimeric antigen receptor redirecting T-cell specificity towards CD26
    Zhou S; Li W; Xiao Y; Zhu X; Zhong Z; Li Q; Cheng F; Zou P; You Y; Zhu X
    Leukemia; 2021 Jan; 35(1):119-129. PubMed ID: 32317776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAR T Cells Generated Using Sleeping Beauty Transposon Vectors and Expanded with an EBV-Transformed Lymphoblastoid Cell Line Display Antitumor Activity In Vitro and In Vivo.
    Chicaybam L; Abdo L; Carneiro M; Peixoto B; Viegas M; de Sousa P; Fornazin MC; Spago MC; Albertoni Laranjeira AB; de Campos-Lima PO; Nowill A; Barros LRC; Bonamino MH
    Hum Gene Ther; 2019 Apr; 30(4):511-522. PubMed ID: 30793967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.
    Richman SA; Nunez-Cruz S; Moghimi B; Li LZ; Gershenson ZT; Mourelatos Z; Barrett DM; Grupp SA; Milone MC
    Cancer Immunol Res; 2018 Jan; 6(1):36-46. PubMed ID: 29180536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 13. CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth.
    Zhou R; Yazdanifar M; Roy LD; Whilding LM; Gavrill A; Maher J; Mukherjee P
    Front Immunol; 2019; 10():1149. PubMed ID: 31178870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Multiple Myeloma Activity of Nanobody-Based Anti-CD38 Chimeric Antigen Receptor T Cells.
    An N; Hou YN; Zhang QX; Li T; Zhang QL; Fang C; Chen H; Lee HC; Zhao YJ; Du X
    Mol Pharm; 2018 Oct; 15(10):4577-4588. PubMed ID: 30185037
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multispecific Targeting with Synthetic Ankyrin Repeat Motif Chimeric Antigen Receptors.
    Balakrishnan A; Rajan A; Salter AI; Kosasih PL; Wu Q; Voutsinas J; Jensen MC; Pl├╝ckthun A; Riddell SR
    Clin Cancer Res; 2019 Dec; 25(24):7506-7516. PubMed ID: 31548346
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pre-clinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma.
    Drent E; Groen RW; Noort WA; Themeli M; Lammerts van Bueren JJ; Parren PW; Kuball J; Sebestyen Z; Yuan H; de Bruijn J; van de Donk NW; Martens AC; Lokhorst HM; Mutis T
    Haematologica; 2016 May; 101(5):616-25. PubMed ID: 26858358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
    Xiong W; Chen Y; Kang X; Chen Z; Zheng P; Hsu YH; Jang JH; Qin L; Liu H; Dotti G; Liu D
    Mol Ther; 2018 Apr; 26(4):963-975. PubMed ID: 29503199
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expanding CAR T cells in human platelet lysate renders T cells with in vivo longevity.
    Torres Chavez A; McKenna MK; Canestrari E; Dann CT; Ramos CA; Lulla P; Leen AM; Vera JF; Watanabe N
    J Immunother Cancer; 2019 Nov; 7(1):330. PubMed ID: 31779709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
    Zhang E; Gu J; Xu H
    Mol Cancer; 2018 Jan; 17(1):7. PubMed ID: 29329591
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of third generation anti-EGFRvIII chimeric T cells and EGFRvIII-expressing artificial antigen presenting cells for adoptive cell therapy for glioma.
    Sahin A; Sanchez C; Bullain S; Waterman P; Weissleder R; Carter BS
    PLoS One; 2018; 13(7):e0199414. PubMed ID: 29975720
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 78.